Condition
High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma
Total Trials
2
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 2 (1)
Trial Status
Unknown2
Clinical Trials (2)
Showing 2 of 2 trials
NCT05276167Not ApplicableUnknownPrimary
Hyperthermic Intravesical Perfusion for Muscle-invasive Bladder Urothelial Carcinoma
NCT05418309Phase 2UnknownPrimary
Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable: a Multi-center Study
Showing all 2 trials